Seres Therapeutics Inc. has announced the publication of two manuscripts in Nature Medicine and the Journal of Infectious Diseases, providing new data on the mechanism and clinical impact of VOWST™, its live biotherapeutic product. The publications highlight clinical translation of VOWST’s mechanism of action in both first and multiply recurrent Clostridioides difficile infection (CDI) patients. The underlying data were developed using the Seres MbTx® platform, which supports the company’s broader live biotherapeutic portfolio, including its lead investigational candidate, SER-155. In a randomized, placebo-controlled Phase 1b study, SER-155 demonstrated a 77% reduction in bacterial bloodstream infections among patients undergoing allogeneic hematopoietic stem cell transplant. The therapy also significantly lowered systemic antibiotic use and incidence of febrile neutropenia. Results from clinical trials and exploratory biomarker data have been presented at medical meetings, supporting the intended mechanisms of the therapy and its potential in inflammatory and immune-mediated diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620244-en) on January 06, 2026, and is solely responsible for the information contained therein.